Ofev
(Nintedanib)Phase 3Small molecule
Boehringer IngelheimNintedanib is used to treat certain types of lung disease, particularly idiopathic pulmonary fibrosis, where the lungs become scarred and stiff over time, making it harder to breathe. It works by slowing down the progression of the disease.[1] Ofev is currently being investigated across 14 indications[3], with its most advanced program in Phase 3.[1]
Ofev is one of 274 small molecule programs targeting Lung Disease. It is currently in Phase 3.
14
Indications
109
Total Trials
13
Active Trials
273
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Ofev
Boehringer IngelheimPhase 3
Bayer Aspirin
BayerPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Mfolfox6
RochePhase 3
Mitosol
UUroGen Pharma Ltd.
Phase 3
TAS 102
Taiho Oncology, Inc.Phase 3
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Thymosin Alpha1
SSun Yat-sen University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Idiopathic Pulmonary Fibrosis13 trials
Show 10 more trials
Interstitial Lung Disease13 trials
Show 10 more trials
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Not yet recruiting·NNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland·Phase 3·NCT06297096·86 enrolled
Non-Small Cell Lung Cancer7 trials
Show 4 more trials
Interaction6 trials
TED4 trials
51 more indications
Drug Interactions4 trials
IPF4 trials
Metastatic Colorectal Cancer3 trials
Lung Disease2 trials
Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT04856111·48 enrolled
Bronchiolitis Obliterans2 trials
Tics2 trials
Fibrosis2 trials
Pulmonary Fibrosis2 trials
Breast Cancer2 trials
Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics
Completed·CCentro Nacional de Investigaciones Oncologicas CARLOS III·Phase 1·NCT02619162·25 enrolled
Scleroderma2 trials
Hepatic Impairment1 trial
Sarcoidosis1 trial
RCT of Nintedanib in Fibrotic Sarcoidosis
Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT06479603·120 enrolled
Malignant Mesothelioma1 trial
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02863055·37 enrolled
Endometrial Cancer1 trial
Hereditary Hemorrhagic Telangiectasia1 trial
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Recruiting·—·Phase 2·NCT04976036·48 enrolled
Adult Subject1 trial
Thyroid Cancer1 trial
Nintedanib(BIBF1120) in Thyroid Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01788982·100 enrolled
ART1 trial
Malignant Pleural Mesothelioma1 trial
Lung Transplantation1 trial
Radiation Pneumonitis1 trial
Small Cell Lung Cancer1 trial
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03377023·66 enrolled
Clear Cell Carcinoma1 trial
Cervix Cancer1 trial
Gastric Adenocarcinoma1 trial
Single Dose1 trial
Soft Tissue Sarcoma1 trial
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02808247·80 enrolled
Pneumoconiosis1 trial
NSCLC1 trial
Acute Myeloid Leukemia1 trial
Metastatic Melanoma1 trial
Metastatic Neuroendocrine Tumor1 trial
Connective Tissue Disease1 trial
Systemic Sclerosis1 trial
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)
Not yet recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT07335562·92 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nintedanib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Platelet-Derived Growth Factor Receptor Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; Fibroblast Growth Factor Receptor Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company